Title : Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.

Pub. Date : 2019 Jul

PMID : 33457057






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039). Paclitaxel BRCA1 DNA repair associated Homo sapiens
2 Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039). Paclitaxel BRCA1 DNA repair associated Homo sapiens
3 The presence of BRCA mutations was not statistically significantly associated with a higher incidence of HSRs to carboplatin, but was statistically significant with regards to paclitaxel. Paclitaxel BRCA1 DNA repair associated Homo sapiens